Liver cancer is a frequent disease. Patients with liver cancer have most of the time an underlying chronic liver disease, often without knowing it since the liver is an organ which does not trigger pain. However, it is possible to cure patients from their liver cancer when the diagnosis is done at an early stage. Therefore diagnostic tools for detecting liver cancer are of utmost importance.
Therapeutically great progresses have been realized in the last years, patients have access to more possible treatments. But the treatment of patients with liver cancer is complex.
The Swiss Foundation against Liver Cancer aims at disseminating information about this disease to increase awareness and to support research to improve the diagnosis, therapy and management of patients and families confronted with this disease.
Join us for an insightful “Ask the Author Session” welcoming Professor Gregory Steinberg, working at McMaster University, where he serves as a professor of medicine and director of the Center of Metabolism, Obesity and Diabetes. Professor Steinberg discusses his very interesting and really great paper published recently in Nature, titled “ACLY Inhibition Promotes Tumor Immunity
For patients fighting hepatocellular carcinoma (HCC), the current standard first-line treatment is typically immuno-oncology, specifically atezolizumab plus bevacizumab (A+B). But what happens when that treatment fails? The optimal subsequent, or second-line, treatment strategy remains “quite open” and “undefined” in clinical practice. Now, groundbreaking real-world evidence from the multinational LEVIATHAN study is challenging previous assumptions and
In a recent “Ask the Author” session, Professor Kudo discussed the LEAP-012 trial and its implications for treating hepatocellular carcinoma (HCC) with Professor Dufour. The study, titled “TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic HCC LEAP-012,” investigates a novel approach to treating this condition. Watch the Full Interview here Background
